CL-316243
Shop CL-316243 on KimeraChems · code GUIDE (10% off)Definition
CL-316243 is a selective β3-adrenergic receptor agonist widely used as a tool compound in metabolic research. It is primarily studied in preclinical models for its ability to activate brown adipose tissue (BAT) thermogenesis and influence energy expenditure, lipolysis, and downstream metabolic-signaling pathways. CL-316243 is not approved for human or veterinary use and is supplied strictly for laboratory and analytical research purposes.
Available Formats
- Concentration: 10 mg/mL
- Total volume: 10 mL
- Total content: 100 mg CL-316243
Mechanism of Action
CL-316243 is studied as a selective β3-adrenergic receptor agonist, with research focused on catecholamine-related signaling in adipose tissue and systemic metabolic regulation. Research suggests it may influence experimental endpoints through several overlapping pathways: Because β3-adrenergic receptor biology differs substantially between species, careful model selection and structured comparator groups are important when interpreting translational findings.
- β3-Adrenergic receptor activation: Studied in adipocytes to model adrenergically driven lipolysis and thermogenic signaling
- Brown adipose tissue activation: Investigated for its ability to increase thermogenesis, frequently including uncoupling protein-1 (UCP1)-related endpoints
- Fatty-acid mobilization: Studied in models examining substrate utilization and mitochondrial oxidative metabolism
- Glucose metabolism: Investigated for potential effects on glucose handling and insulin-sensitivity-related endpoints in preclinical models where adipose activation is a primary experimental variable
Areas of Investigation
CL-316243 is commonly studied in
- Brown-adipose-tissue activation and thermogenesis research
- Lipolysis and fatty-acid-mobilization models
- Energy-expenditure and metabolic-rate studies in controlled preclinical designs
- Insulin-sensitivity and glucose-metabolism research involving adipose signaling
- Adipose-tissue browning and mitochondrial-biogenesis endpoints in rodent models
- Sympathetic-signaling and adrenergic-pathway mapping studies
Safety Profile
Reported observations are model- and exposure-dependent and may include
- Tachycardia-like findings or increased sympathetic-tone markers, particularly when receptor selectivity is reduced at higher exposure levels
- Tremor-like or agitation-like behaviors in adrenergic-sensitive models
- Blood-pressure-related changes depending on experimental design and measurement conditions
- Confounded metabolic outcomes when combined with potent stimulants or thyroid-axis-active interventions
Interaction Notes
CL-316243 is often explored alongside interventions that overlap with adrenergic and metabolic signaling.
For educational purposes only. Not for human consumption.